[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial
- Author(s)
- Emmett, L; Subramaniam, S; Crumbaker, M; Nguyen, A; Joshua, AM; Weickhardt, A; Lee, ST; Ng, S; Francis, RJ; Goh, JC; Pattison, DA; Tan, TH; Kirkwood, ID; Gedye, C; Rutherford, NK; Sandhu, S; Kumar, AR; Pook, D; Ramdave, S; Nadebaum, DP; Voskoboynik, M; Redfern, AD; Macdonald, W; Krieger, L; Schembri, G; Chua, W; Lin, P; Horvath, L; Bastick, P; Butler, P; Zhang, AY; Yip, S; Thomas, H; Langford, A; Hofman, MS; McJannett, M; Martin, AJ; Stockler, MR; Davis, ID; ENZA-p Trial Investigators; Australian and New Zealand Urogenital and Prostate Cancer Trials Group;
- Details
- Publication Year 2024-05,Volume 25,Issue #5,Page 563-571
- Journal Title
- Lancet Oncology
- Publication Type
- Research article
- Abstract
- BACKGROUND: Enzalutamide and lutetium-177 [(177)Lu]Lu-prostate-specific membrane antigen (PSMA)-617 both improve overall survival in patients with metastatic castration-resistant prostate cancer. Androgen and PSMA receptors have a close intracellular relationship, with data suggesting complementary benefit if targeted concurrently. In this study, we assessed the activity and safety of enzalutamide plus adaptive-dosed [(177)Lu]Lu-PSMA-617 versus enzalutamide alone as first-line treatment for metastatic castration-resistant prostate cancer. METHODS: ENZA-p was an open-label, randomised, controlled phase 2 trial done at 15 hospitals in Australia. Participants were men aged 18 years or older with metastatic castration-resistant prostate cancer not previously treated with docetaxel or androgen receptor pathway inhibitors for metastatic castration-resistant prostate cancer, gallium-68 [(68)Ga]Ga-PSMA-PET-CT (PSMA-PET-CT) positive disease, Eastern Cooperative Oncology Group performance status of 0-2, and at least two risk factors for early progression on enzalutamide. Participants were randomly assigned (1:1) by a centralised, web-based system using minimisation with a random component to stratify for study site, disease burden, use of early docetaxel, and previous treatment with abiraterone acetate. Patients were either given oral enzalutamide 160 mg daily alone or with adaptive-dosed (two or four doses) intravenous 7·5 GBq [(177)Lu]Lu-PSMA-617 every 6-8 weeks dependent on an interim PSMA-PET-CT (week 12). The primary endpoint was prostate-specific antigen (PSA) progression-free survival, defined as the interval from the date of randomisation to the date of first evidence of PSA progression, commencement of non-protocol anticancer therapy, or death. The analysis was done in the intention-to-treat population, using stratified Cox proportional hazards regression. This trial is registered with ClinicalTrials.gov, NCT04419402, and participant follow-up is ongoing. FINDINGS: 162 participants were randomly assigned between Aug 17, 2020, and July 26, 2022. 83 men were assigned to the enzalutamide plus [(177)Lu]Lu-PSMA-617 group, and 79 were assigned to the enzalutamide group. Median follow-up in this interim analysis was 20 months (IQR 18-21), with 32 (39%) of 83 patients in the enzalutamide plus [(177)Lu]Lu-PSMA-617 group and 16 (20%) of 79 patients in the enzalutamide group remaining on treatment at the data cutoff date. Median age was 71 years (IQR 64-76). Median PSA progression-free survival was 13·0 months (95% CI 11·0-17·0) in the enzalutamide plus [(177)Lu]Lu-PSMA-617 group and 7·8 months (95% CI 4·3-11·0) in the enzalutamide group (hazard ratio 0·43, 95% CI 0·29-0·63, p<0·0001). The most common adverse events (all grades) were fatigue (61 [75%] of 81 patients), nausea (38 [47%]), and dry mouth (32 [40%]) in the enzalutamide plus [(177)Lu]Lu-PSMA-617 group and fatigue (55 [70%] of 79), nausea (21 [27%]), and constipation (18 [23%]) in the enzalutamide group. Grade 3-5 adverse events occurred in 32 (40%) of 81 patients in the enzalutamide plus [(177)Lu]Lu-PSMA-617 group and 32 (41%) of 79 patients in the enzalutamide group. Grade 3 events that occurred only in the enzalutamide plus [(177)Lu]Lu-PSMA-617 group included anaemia (three [4%] of 81 participants) and decreased platelet count (one [1%] participant). No grade 4 or 5 events were attributed to treatment on central review in either group. INTERPRETATION: The addition of [(177)Lu]Lu-PSMA-617 to enzalutamide improved PSA progression-free survival providing evidence of enhanced anticancer activity in patients with metastatic castration-resistant prostate cancer with risk factors for early progression on enzalutamide and warrants further evaluation of the combination more broadly in metastatic prostate cancer. FUNDING: Prostate Cancer Research Alliance (Movember and Australian Federal Government), St Vincent's Clinic Foundation, GenesisCare, Roy Morgan Research, and Endocyte (a Novartis company).
- Publisher
- Elsevier
- Keywords
- Humans; Male; *Prostatic Neoplasms, Castration-Resistant/drug therapy/pathology/mortality; *Phenylthiohydantoin/administration & dosage/therapeutic use/analogs &; derivatives; *Benzamides; Aged; *Nitriles; *Lutetium; *Dipeptides/therapeutic use/administration & dosage/adverse effects; *Heterocyclic Compounds, 1-Ring/therapeutic use/administration & dosage/adverse; effects; Middle Aged; *Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Prostate-Specific Antigen/blood; Progression-Free Survival; Radioisotopes/therapeutic use; Aged, 80 and over; Radiopharmaceuticals
- Department(s)
- Cancer Imaging; Medical Oncology
- Publisher's Version
- https://doi.org/10.1016/s1470-2045(24)00135-9
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2024-07-04 04:37:48
Last Modified: 2024-07-04 04:49:35